On October 1, 2019, the Delaware Court of Chancery issued its decision in In re Clovis Oncology, Inc. Derivative Litigation, C.A. No. 2017-0222-JRS (Del. Ch. Oct. 1, 2019), which addresses the duties of directors to oversee...more
10/30/2019
/ Board of Directors ,
Breach of Duty ,
Caremark claim ,
Clinical Trials ,
Corporate Governance ,
DE Supreme Court ,
Derivative Suit ,
Enforcement Actions ,
Internal Controls ,
Oversight Duties ,
Pharmaceutical Industry ,
Popular ,
Securities and Exchange Commission (SEC)